Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NeuroPace (NPCE) Research & Development (2020 - 2025)

Historic Research & Development for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to $6.6 million.

  • NeuroPace's Research & Development rose 1428.57% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year increase of 1710.62%. This contributed to the annual value of $23.7 million for FY2024, which is 1383.68% up from last year.
  • As of Q3 2025, NeuroPace's Research & Development stood at $6.6 million, which was up 1428.57% from $6.8 million recorded in Q2 2025.
  • NeuroPace's 5-year Research & Development high stood at $7.4 million for Q1 2025, and its period low was $4.1 million during Q1 2021.
  • Its 5-year average for Research & Development is $5.5 million, with a median of $5.6 million in 2022.
  • The largest annual percentage gain for NeuroPace's Research & Development in the last 5 years was 3643.91% (2021), contrasted with its biggest fall of 1516.66% (2021).
  • NeuroPace's Research & Development (Quarter) stood at $5.3 million in 2021, then dropped by 4.79% to $5.1 million in 2022, then grew by 5.66% to $5.4 million in 2023, then rose by 12.52% to $6.0 million in 2024, then rose by 8.69% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $6.8 million for Q2 2025, and $7.4 million during Q1 2025.